A computational model of 1,5-AG dynamics during pregnancy

Area of Science:

• Biomedical Engineering
• Reproductive Endocrinology
• Clinical Chemistry

Background:

• 1,5-anhydroglucitol (1,5-AG) is a vital biomarker for moderate glycemic control in pregnancy, predicting risks for gestational diabetes and eclampsia.
• Physiological changes during pregnancy, such as altered glomerular filtration rate and plasma volume, complicate the clinical interpretation of serum 1,5-AG levels.
• Existing models have not fully accounted for these gestational hemodynamics, limiting the biomarker's utility.

Purpose of the Study:

• To develop and validate an in-silico model of 1,5-AG kinetics during normal and diabetic pregnancies.
• To quantitatively assess the impact of renal and hemodynamic factors on gestational 1,5-AG concentrations.
• To aid in the clinical interpretation of 1,5-AG levels throughout pregnancy.

Main Methods:

• Developed a two-compartment mathematical model for 1,5-AG kinetics, integrating existing physiological data.
• Adapted a previously established kinetic model (Stickle and Turk, 1997) for the gestational context.
• Simulated 1,5-AG concentrations considering adjustments for pregnancy duration and renal reabsorption fraction.

Main Results:

• The two-compartment model accurately simulated 1,5-AG kinetics through the first two trimesters of both normal and diabetic pregnancies.
• Adjusting the reabsorption fraction after 25 weeks improved model accuracy for the third trimester.
• The model confirmed the influence of renal and hemodynamic changes on 1,5-AG levels during pregnancy.

Conclusions:

• The developed in-silico model provides a quantitative framework for understanding 1,5-AG dynamics in pregnancy.
• This model clarifies how physiological changes affect 1,5-AG measurements, enhancing clinical utility.
• Further research is needed to elucidate third-trimester specific changes and differences between diabetes subtypes.